SAFETY OF ERADICATION THERAPY OF HELICOBACTER PYLORI INFECTION: SYSTEMATIZATION OF LITERATURE DATA


D.N. Andreev, I.V. Mayev, A.A. Samsonov, E.G. Lobanova, E.V. Partsvania-Vinogradova

FSBEI HE “Moscow State Medical Stomatological University n.a. A.I. Evdokimov” of RMH, Moscow
The article systematizes literature data on the safety of eradication therapy (ET) of Helicobacter pylori infection. Data on the individual safety profile and tolerability of antibacterial drugs included in the ET regimens are presented. It is shown that the risk of development of side effects with the use of ET is 24% on average and varies depending on the specific treatment regimen: triple therapy with cla-rithromycin (21–24%), triple therapy with metronidazole (30%), bismuth-containing quadrupletherapy (23%), quadrupletherapy therapy without bismuth preparations (24%), sequential therapy (22%), triple therapy with levofloxacin (15–27%), hybrid therapy (26–32.9%). The factors that increase the risk of side effects include the duration of the course of therapy, incorrect dosage of drugs, the presence of concomitant liver pathology, including cirrhosis. A significant reduction in the incidence of side effects associated with ET can be achieved only with the use of adjuvant therapy with the probiotics.

About the Autors


Corresponding author: D.N. Andreev – PhD, Teaching Assistant at the Department of Propaedeutics of Internal Diseases and Gastroenterology FSBEI HE MSMSU n.a. A.I. Evdokimov of RMH, Moscow; e-mail: dna-mit8@mail.ru


Similar Articles


Бионика Медиа